Immunovant (IMVT)
NASDAQ:IMVT
Holding IMVT?
Track your performance easily

Immunovant (IMVT) Financial Statements

745 Followers

Immunovant Financial Overview

Immunovant's market cap is currently ―. The company's EPS TTM is $-1.917; its P/E ratio is -15.07; Immunovant is scheduled to report earnings on November 1, 2024, and the estimated EPS forecast is $-0.59. See an overview of income statement, balance sheet, and cash flow financials.
Jun 24Mar 24Sep 23Jun 23Mar 23
Income Statement-
Total Revenue-----
Gross Profit-----
EBIT$ -87.07M$ -83.47M$ -61.78M$ -78.01M$ -60.42M
EBITDA$ -86.93M$ -83.15M$ -61.43M$ -77.67M$ -60.08M
Net Income Common Stockholders$ -87.15M$ -75.32M$ -58.66M$ -73.94M$ -59.43M
Balance Sheet-
Cash, Cash Equivalents and Short-Term Investments$ 560.00M$ 635.37M$ 269.93M$ 329.96M$ 376.53M
Total Assets$ 589.68M$ 666.37M$ 292.07M$ 351.22M$ 405.50M
Total Debt$ 69.00K$ 138.00K$ 614.00K$ 919.00K$ 1.22M
Net Debt$ -559.94M$ -635.23M$ -269.31M$ -329.04M$ -375.31M
Total Liabilities$ 45.02M$ 48.61M$ 40.26M$ 51.36M$ 43.34M
Stockholders Equity$ 544.66M$ 617.76M$ 251.81M$ 299.87M$ 362.49M
Cash Flow-
Free Cash Flow$ -76.38M$ -59.85M$ -60.09M$ -47.41M$ -55.82M
Operating Cash Flow$ -76.20M$ -59.70M$ -60.06M$ -47.37M$ -55.79M
Investing Cash Flow$ -182.00K$ -150.00K$ -34.00K$ -45.00K$ -26.00K
Financing Cash Flow$ 686.00K$ 1.54M$ 148.00K$ 890.00K$ 233.00K
Currency in USD

Immunovant Earnings and Revenue History

Immunovant Debt to Assets

Immunovant Cash Flow

Immunovant Forecast EPS vs Actual EPS

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis